Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Wenn bei HER2-positivem Brustkrebs nach der neoadjuvanten Therapie vor der Operation noch Resttumor nachweisbar ist, kann sich der Einsatz eines bestimmten Antikörper-Wirkstoff-Konjugats lohnen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback